People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

It is believed around 1,700 people could be eligible for the treatment, while the NHS estimates around 50 people a year will ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...